Health and productivity losses from obesity far outstrip weight-loss jab costs'

"The economic burden of obesity is staggering, with costs to the UK estimated at £100 billion annually, demonstrating a significant opportunity for weight-loss medications to mitigate these expenses."

"The report highlights that while Wegovy carries a higher price tag, the overall financial implications of obesity far exceed the costs associated with these new GLP-1 drugs."

Read at www.theguardian.com